Core Insights - Abbott Laboratories' Nutrition business is experiencing strong growth and market share gains, driven by high demand for adult nutritional products that combine high protein and low sugar [1][7] - The global nutritional supplements market is projected to reach $704.28 billion by 2030, growing at a CAGR of 6.42% from 2025 to 2030, influenced by increased health consciousness post-COVID-19 and rising non-communicable diseases [2] - Abbott's brands, Ensure and Glucerna, are leading in the market for complete nutrition, while the Similac brand remains the top choice for pediatric nutrition in the U.S. [3][7] Company Performance - Abbott's adult Nutrition segment achieved 6.6% organic growth in Q2 2025, contributing to mid-single-digit organic growth overall [3][7] - Year-to-date, Abbott shares have increased by 16.5%, outperforming the industry growth of 5.9% and the S&P 500's 9.6% [6] Competitive Landscape - Nestlé's Nutrition business offers a wide range of products for all life stages, including infant formulas and adult nutritional drinks [4] - Danone specializes in Early Life Nutrition and Medical Nutrition, providing a variety of infant and child nutrition products as well as condition-specific solutions [5] Valuation Metrics - Abbott currently trades at a forward Price-to-Sales (P/S) ratio of 4.89X, below the industry average of 5.56X [8]

Core Insights - FitLife Brands, Inc. reported a 5% decrease in total revenue for Q2 2025, amounting to $16.1 million compared to $16.9 million in Q2 2024 [3][19] - The decline in online revenue was 7%, totaling $10.4 million, which represented 65% of total revenue for the quarter [3][19] - Gross margin decreased to 42.8% from 44.8% year-over-year, primarily due to increased merger and acquisition-related expenses [4][5][19] Financial Performance - Net income for Q2 2025 was $1.7 million, down from $2.6 million in Q2 2024, with basic and diluted earnings per share at $0.19 and $0.18, respectively [5][19] - Adjusted EBITDA decreased by 13% to $3.3 million compared to the same period in 2024, with trailing twelve months adjusted EBITDA at $13.4 million [6][19] - The company ended the quarter with $10.9 million in term loans and $6.6 million in cash, resulting in total net debt of $4.3 million, approximately 0.3x adjusted EBITDA [7][19] Brand Performance - Legacy FitLife revenue increased by 7% year-over-year, driven by a 17% increase in online revenue and a 1% increase in wholesale revenue [11][12] - MRC revenue decreased by 16% compared to Q2 2024, with significant declines in the Dr. Tobias brand and skin care brands due to reduced traffic and tariffs [13][14][15] - MusclePharm revenue decreased by 4%, with wholesale revenue down 6% and online revenue down 3%, although the company is investing in advertising to drive growth [17][18][24] Acquisition Activity - The company completed the acquisition of Irwin Naturals for $42.5 million on August 8, 2025, funded primarily through a new term loan and available cash [20][26] - Irwin Naturals generated approximately $60 million in revenue with a gross margin of about 35% for the trailing twelve months as of June 30, 2025 [25][26] - Management expects to achieve cost savings and improved gross margins as they integrate Irwin Naturals into their operations [26][27]

Vancouver, British Columbia – August 13, 2025 – TheNewswire - Pangea Natural Foods Inc. (CSE: PNGA) (OTC: PNGAF) ("Pangea" or the "Company") is pleased to announce that its subsidiary Amino Innovations successfully showcased its portfolio of science-backed, non-injectable peptide products at TheFitExpo in Anaheim, California. The event, held on August 2nd-3rd at the Anaheim Convention Center, attracted more than 20,000 attendees, including fitness enthusiasts, trainers, wellness professionals, and influence ...

Core Viewpoint - FitLife Brands, Inc. has successfully acquired substantially all assets of Irwin Naturals for a total consideration of $42.5 million, as approved by the US Bankruptcy Court [1][2]. Group 1: Acquisition Details - The acquisition was executed under Section 363 of the US Bankruptcy Code, allowing FitLife to acquire assets while assuming minimal liabilities [2]. - The funding for the acquisition included $35.75 million from a new term loan and revolving line of credit from First Citizens Bank, with the remainder sourced from FitLife's cash balances [2]. Group 2: Company Insights - FitLife Brands is a developer and marketer of nutritional supplements and wellness products, offering over 250 products primarily online and through various retail locations [3]. - The company is headquartered in Omaha, Nebraska, and targets health-conscious consumers [3]. Group 3: Management Commentary - Dayton Judd, Chairman and CEO of FitLife, expressed excitement about the acquisition, highlighting Irwin's strong brands and distribution capabilities, and anticipates it will drive revenue and earnings growth for the company [3].

Financial Data and Key Metrics Changes - Net sales for Q2 2025 were $1.3 billion, down 1.7% compared to 2024, but flat on a constant currency basis [7][24] - Adjusted EBITDA was $174 million, exceeding guidance, with an adjusted EBITDA margin of 13.8%, down 30 basis points year over year due to unfavorable currency impacts [24][27] - The company paid down $55 million in debt during the quarter, maintaining a total leverage ratio of slightly under three times as of June 30 [27][28] Business Line Data and Key Metrics Changes - Product innovation included the launch of Multi Burn, a non-pharmaceutical weight loss supplement, and the introduction of a healthy lifespan product [6][19] - Distributor growth initiatives led to strong engagement, with nearly 38,000 attendees at training events globally [9][10] - New distributor growth was flat year over year, but four out of five regions saw increases, with Latin America leading at 16% growth [9] Market Data and Key Metrics Changes - In North America, net sales were down 4%, primarily due to a 6% decline in year-over-year volumes, but July marked the first month of year-over-year volume growth since April 2021 [33][8] - Latin America reported a strong performance with constant currency net sales up 9%, despite reported net sales being down 1% [31] - EMEA net sales were flat on a reported basis, while Asia Pacific saw a 2% decline in reported net sales [32] Company Strategy and Development Direction - The company aims to transform into a data-driven wellness platform, integrating technology and personalized solutions to meet evolving consumer needs [4][5] - The acquisition of Link Biosciences is expected to enhance personalized supplement formulations, providing a competitive advantage [21] - The company is focused on expanding its product offerings and enhancing distributor engagement through digital tools and AI [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and noted signs of accelerating momentum in sales [5][8] - The outlook for Q3 includes projected net sales growth of 0.5% to 4.5% year over year, with adjusted EBITDA expected to be between $150 million and $160 million [38][39] - The company has raised and narrowed its full-year net sales guidance range to down 1% to up 3% year over year [39][40] Other Important Information - The company is integrating the Protocol app, which aims to enhance distributor-customer connections and provide personalized health insights [11][12] - The launch of the Protocol app is expected to create new monetization opportunities and attract a new customer segment [48][63] - The company plans to expand the Protocol platform globally, with regulatory assessments underway for key markets [68] Q&A Session Summary Question: What are the monetization strategies for the Protocol app? - Management indicated that the app will serve as a tool for distributors to enhance customer engagement and will have options for both product and app subscriptions [48][63] Question: How does the company view pricing in relation to competitors? - The company plans to take pricing in line with market conditions and has not seen significant pressure from competitors [56][58] Question: What are the plans for high-cost debt management? - The company is considering refinancing options for high-cost debt as market conditions improve [69]

Core Viewpoint - FitLife Brands, Inc. has announced the acquisition of substantially all assets of Irwin Naturals, a nutritional supplement company, under Section 363 of the US Bankruptcy Code, with the transaction expected to close around August 8, 2025 [1][2]. Transaction Highlights - The purchase price for the acquisition is $42.5 million, which includes approximately $16 million of net working capital and equates to a pre-synergy acquisition multiple of less than 6x EBITDA [8][9]. - The combined revenue for the first full year of operation is anticipated to exceed $120 million, with adjusted EBITDA expected to be between $20-25 million [8][9]. About Irwin Naturals - Irwin Naturals, founded in 1994, generates approximately 4% of its revenue from online sales, 61% from wholesale sales to mass market customers, and 35% from wholesale sales to health food stores [3]. - Major mass market customers for Irwin include CVS, Walmart, Walgreens, and Costco Canada [3]. Rationale for the Transaction - The product lines of FitLife and Irwin are largely complementary, with Irwin strong in weight loss, sexual wellness, and body cleanse segments, while FitLife focuses on sports nutrition [5]. - The acquisition is expected to enhance revenue growth through complementary channel strengths, particularly in the food, drug, and mass market channels where FitLife currently has minimal revenue [6]. - FitLife anticipates operational synergies that will allow for more profitable operations of Irwin, including an expected reduction of approximately $1.5 million in SG&A costs [7]. Financing Arrangements - The transaction will be funded through a combination of cash on hand and a new committed term loan of $40.625 million, along with an upsized $10 million revolving credit facility from First Citizens Bank [8][9]. - Pre-synergy total leverage at closing is expected to be less than 2.25x EBITDA [8]. Company Performance Expectations - For the second quarter of 2025, FitLife expects a year-over-year revenue decline of approximately 4-5%, attributed mainly to the performance of a specific product under the Dr. Tobias brand [11][12]. - The company anticipates net income for the second quarter to be between $1.6 - 1.8 million, including transaction-related expenses [12].

Core Viewpoint - FitLife Brands, Inc. plans to report its financial performance for Q2 of fiscal 2025 on August 14, 2025 [1] Group 1: Financial Reporting - The financial performance report for Q2 fiscal 2025 will be released on August 14, 2025 [1] - An investor conference call is scheduled for August 14, 2025, at 4:30 pm ET [2] - Participants can join the call using specific dial-in numbers and a conference identification code [2] Group 2: Company Overview - FitLife Brands is a developer and marketer of nutritional supplements and wellness products [3] - The company offers over 250 different products, primarily marketed online and through GNC® franchise locations [3] - FitLife Brands is headquartered in Omaha, Nebraska [3]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $115 million, a 4% increase year-over-year or 2% in constant currency [6][14] - Adjusted EBITDA for Q2 was $11 million, an 8% increase from $10 million in the prior year [6][22] - GAAP net income attributable to common shareholders was $5.3 million or $0.28 per diluted share, compared to $1.3 million or $0.07 per diluted share in the prior year [22] - Gross margin increased by 36 basis points to 71.7% compared to the previous year [20] Business Line Data and Key Metrics Changes - North America sales grew 4%, with digital sales increasing by 34% [10][15] - Asia Pacific sales increased by 5%, driven by a 27% increase in Japan [7][16] - Europe sales were up 1% but down 2% in constant currency, with Central Europe showing strong growth of 15% [12][19] Market Data and Key Metrics Changes - In North America, the digital business saw significant growth, contributing to overall sales growth [10][15] - Japan's sales growth was notable, with a consistent 20%+ growth for four consecutive quarters [16] - Taiwan and South Korea faced challenges due to a slowing macroeconomic environment, impacting sales growth [9][18] Company Strategy and Development Direction - The company is focused on long-term sustainable growth through strong consumer engagement and execution of sales and marketing strategies [6][7] - The strategy includes sharpening digital execution, stabilizing the core business in North America, and driving growth in key international markets [12][13] - The company is increasing its full-year guidance based on strong first-half performance and positive momentum [13][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macroeconomic uncertainties but expressed confidence in the company's fundamentals and growth strategy [6][7] - The outlook for the second half of the year includes expectations for continued growth in North America and stabilization in Asia Pacific [55][56] - Management is optimistic about future growth prospects, particularly in digital sales and new product innovations [25][62] Other Important Information - The company repurchased 1.1 million shares for approximately $12.3 million during the first half of 2025 [23] - Inventory increased to $69.3 million as the company prepared for potential supply chain disruptions [23] Q&A Session Summary Question: Clarification on EBITDA guidance range - Management indicated that the range reflects confidence in North America and the digital business, with performance dependent on continued acceleration [27][28] Question: Insights on SG&A expenses and digital investment - Management confirmed increased digital investment in Q2, with plans to continue funding if strong returns are observed [32][34] Question: Impact of new product innovations - New products are expected to provide consumer energy and acquisition, with cumulative effects anticipated over time [61][62] Question: Capacity and potential partnerships - The company is exploring opportunities to leverage increased manufacturing capacity through organic growth and potential partnerships [40][41] Question: Growth expectations in North America and Asia - Continued acceleration in North America is expected, while Asia Pacific will see growth but at lower rates compared to previous quarters [51][55]

Core Viewpoint - Nature's Sunshine Products, Inc. reported a strong second quarter for 2025, with net sales of $115 million and adjusted EBITDA of $11 million, reflecting year-over-year increases of 4% and 8% respectively, driven by growth in Japan, Central Europe, and digital business initiatives [2][7]. Financial Performance - Net sales for the second quarter of 2025 were $114.8 million, up from $110.6 million in the same quarter of 2024, marking a 4% increase. Excluding foreign exchange impacts, net sales increased by 2% [3][7]. - Adjusted EBITDA rose to $11.3 million, an 8% increase from $10.4 million in the prior year quarter, primarily due to higher net sales [10]. - GAAP net income attributable to common shareholders increased to $5.3 million, or $0.28 per diluted share, compared to $1.3 million, or $0.07 per diluted share, in the same quarter of 2024 [9][10]. Segment Performance - Sales by region showed varied performance: - Asia: $52.7 million, up 5.4% - Europe: $21.7 million, up 0.6% - North America: $35.0 million, up 4.2% - Latin America and Other: $5.4 million, down 0.6% [3]. Cost and Expenses - Gross profit margin improved to 71.7% from 71.4% year-over-year, attributed to cost-saving initiatives despite foreign exchange challenges [4]. - Selling, general and administrative expenses (SG&A) increased to $43.7 million from $38.6 million, representing 38.1% of net sales compared to 34.9% in the previous year [5]. Income and Cash Flow - Operating income decreased to $4.3 million, or 3.7% of net sales, down from $5.6 million, or 5.1% of net sales, in the prior year [6]. - Net cash provided by operating activities for the first half of 2025 was $6.9 million, compared to $3.5 million in the same period of 2024 [11]. Outlook - The company expects full-year 2025 net sales to range between $460 million and $475 million, and adjusted EBITDA to range between $41 million and $45 million, reflecting an optimistic outlook despite macroeconomic uncertainties [12].

全粉色沉浸式展位，传递 "母婴友好" 初心 花颜 28—— 日 "养" 根基，状态吃饱不掉线 汇集 28 种自然养分，花颜 28 为女性提供全面支持。从日常补充，到孕期营养储备及产后修复，通过平 衡代谢需求，以细密滋养守护生命绽放，成为母婴健康路上的贴心伙伴。 metoday 展位以全粉色为主视觉，用柔和灯光与通透陈设构建起温暖治愈的沉浸式空间。不同于传统母 婴场景的刻意呈现，这里通过色彩与氛围的细腻表达，将 "母婴友好" 的理念融入每一处细节。温柔的 粉色基调呼应着女性对 "温和、安心" 的需求，通透的布局与舒适的动线让参观者在放松的氛围中感受 品牌温度。以自然舒展的姿态传递着品牌对母婴群体的重视，让 "自内而外的滋养" 从产品延伸至体 验，用氛围诉说这一女性需求的深层理解。 三大主推品亮相，构建营养解决方案 补铁爆珠 ——"红" 粉佳人，面若桃花不用妆 针对全年龄段女性气血需求，metoday 补铁爆珠以独特配方激活血红蛋白活力，让红润气色自然晕染。 无论是孕期妈妈还是职场女性，都能通过温和滋养重获元气，从容应对生活挑战。 虾青素 —— 日透 "光" 感，暗黄退散 聚焦内服防晒新趋势，虾青素以高活性抗氧化 ...